Upright computed tomography showed stable numbers for proton therapy planning
Upright computed tomography showed stable computed tomography numbers and greater than 99% proton dose gamma agreement versus conventional computed tomography.
Upright computed tomography showed stable computed tomography numbers and greater than 99% proton dose gamma agreement versus conventional computed tomography.
All eight radiotherapy planning computed tomography scanners showed measurable geometric distortion, with maximum values up to 1.88 millimetres.
An automated report-based chart checker detected residual errors in 37.1% of manually reviewed external beam radiotherapy plans.
Simultaneous integrated boost radiotherapy was associated with 96% two-year disease-free survival versus 70% with sequential boost in anal cancer.
Daily cone-beam computed tomography-based adaptation improved prostate stereotactic body radiotherapy target coverage, but organ-at-risk dose benefits were inconsistent.
Thermo-optical surface monitoring with X-ray correction kept breast deep inspiration breath-hold setup errors within clinical tolerance.
Photogrammetry-derived body surface models enabled Monte Carlo evaluation of total skin electron therapy dose homogeneity and hot-cold spot locations.
Aperture irregularity and modulation complexity score were the strongest plan-complexity predictors of patient-specific quality assurance pass rate.
A shared-source Eclipse toolkit unified lattice generation, position-aware optimization, and peak-valley dose ratio evaluation for spatially fractionated radiation therapy.
N4 bias correction with z-score normalization produced the most stable radiomic features on a 0.35 tesla magnetic resonance linear accelerator.
Daily magnetic resonance-informed adaptation increased target coverage by 14% and reduced bowel dose by 7% for pelvic lymph node metastases.
Scanned and scattered clinical proton beams produced similar Ewing sarcoma cell survival despite higher oxidative stress signals after scanned delivery.
Diagnostic computed tomography-based single-fraction radiotherapy was feasible for selected non-spine palliative metastases, with no grade 3 or higher acute toxicity.
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.
All patients receiving more than 8 Gy mean dose or 16 Gy maximum dose to the least exposed ovary developed premature ovarian insufficiency.